Allied Market Research
Loading...
Cart
0
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

New
New Allied Market Research

U.S. Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications), Pain Type (Chronic and Acute): Opportunity Analysis and Industry Forecast, 2020–2027

A09451
Pages: 153
Jan 2021 | 363 Views
 
Author(s) : Ravi Telugunta, Apoorva Srivastava , Onkar Sumant
Tables: 34
Charts: 57
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the U.s. Pain Management Drugs Market

Request Now !

U.S. Pain Management Drugs Market Overview:

The U.S. pain management drugs market size was valued at $31,499.07 million in 2019, and is projected to reach $39,356.45 million by 2027, registering a CAGR of 3.4%. 

The COVID-19 pandemic has stressed healthcare systems in U.S., so that many clinics, pain services are no longer open for public services because of safety. However, the telemedicine has become an appropriate and effective way to provide necessary medical services to patients with pain, which drives the market growth in near future.

Pain is an uncomfortable sensory and emotional sensation caused due to tissue injury or disease. It is caused due to injury and various diseases such as osteoarthritis, chronic arthritis, diabetic neuropathy, multiple sclerosis, stomach ulcer, fibromyalgia and cancer. It can be defined as acute pain and chronic pain depending on duration.

US-Pain-Management-Drugs-Market-2020-2027

Get more information on this report : Request Sample Pages

This pandemic has disrupted growth in many economies across various domains. The COVID-19 outbreak is anticipated to impact the growth of the pain management drugs market in the initial phase of the forecast period. The COVID-19 pandemic has stressed healthcare systems in the U.S., so that pain services in many clinics are no longer open for public services because of safety. Furthermore, the demand for pain management drugs is expected to rise during the latter half of the forecast period owing to telemedicine which has become an appropriate and effective way to offer necessary medical services to patients with chronic pain. Through telemedicine, physicians are able to provide guidance to patients for physical exercises at-home for pain relief.

Chronic pain is mainly caused due to aging conditions of bone and joints and nerve damage and injury. Pain is managed by a particular set of drugs to reduce the symptoms or treat pain. Pain process is complex and there are various drugs that provide relief by acting through a variety of physiological mechanism. Opioids are the most prescribed pain medication. These are narcotic pain medications containing natural and synthetic opiates. Opioids are usually used for acute pain, such as short-term pain after surgery. Morphine, Fentanyl, Oxycodone and Codeine are some of the opioids used for pain management.

As per the statistics by the National Cancer Institute, around 9.5 million individuals were reported to be suffering from cancer in the U.S. in 2019, and this number is expected to increase to 19 million in 2024. This is expected to increase the need of cancer pain drugs for therapeutic purposes, thus fueling the U.S. pain management drugs market growth. 

In recent times there is increased use of pain management drugs due to rise in aging population. Increasing prevalence of diseases such as cancer, diabetic neuropathy, osteoarthritis and chronic arthritis, increasing number of surgical procedures and increasing healthcare expenditure are some of the key factors driving the growth for the U.S. pain management drugs market. In addition, increasing healthcare awareness is also fuelling the growth of U.S. pain management drugs market. However, increase in generic completion, patent expiration of blockbuster drugs and availability of substitutes such as pain relief devices are some of the major factors restraining the growth for U.S. pain management drugs market. In addition, prescribing drug abuse would inhibit the growth of the market. 

Increasing R&D investment and outsourcing of pharmaceutical companies due to strong need for better treatment lead to market growth. In addition, novel molecule combination and drug delivery techniques would develop opportunity for the U.S. pain management drugs market. However, side effects of pain management drugs could lead a challenge for the pain management drugs market.

U.S. Pain Management Drugs Market
By Drug Class

Your browser does not support the canvas element.

Blood products holds the dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

U.s. Pain Management Drugs Market Segmentation

The U.S. pain management drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, it is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia, bone fracture, muscle sprain, acute appendicitis and other indications.  On the basis of pain type, it is segmented into chronic pain and acute pain.

Segment review

On the basis of drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anesthetics segment is anticipated to possess highest growth rate during the forecast period. 

U.S. Pain Management Drugs Market
By Indication

Your browser does not support the canvas element.

Neuropathic Pain segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

By indication, the neuropathic pain segment accounted for a majority of the U.S. pain management drugs market share in 2019, and is expected to exhibit a prominent growth rate during the forecast period. In addition, increase in presence of large patient population is the major factor that increases demand for drugs for the segment. Cancer pain segment are expected to grow at the highest rate throughout the forecast period, owing to increase in number of surgeries and rise in prevalence of chronic diseases that lead to back pain.

The key players operating in the U.S. pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Purdue Pharma L.P., Boehringer Ingelheim, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc.

U.S. Pain Management Drugs Market
By Pain type

2027
Chronic Pain 
Acute Pain

Chronic Pain holds the dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the U.S. pain management drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
  • Quantitative analysis from 2019 to 2027 is expected to enable the stakeholders to capitalize on prevailing U.S. pain management drugs market opportunities.
  • The U.S. pain management drugs market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • Extensive analysis is conducted by closely following key product positioning and monitoring the top contenders within the market framework.

Key Market Segments

By Drug Class

  • NSAIDS
  • Anesthetics
  • Anticonvulsants
  • Antimigraine Agents
  • Antidepressants
  • Opioids 
  • Nonnarcotic Analgesics 

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Bone fracture
  • Muscle sprain/strain
  • Acute appendicitis 
  • Others 

By Pain type 

  • Chronic pain
  • Acute pain 
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Top player positioning
3.4.Porter’s five force analysis
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in incidences of chronic diseases
3.5.1.2.Favorable regulatory scenario
3.5.1.3.Increase in geriatric population

3.5.2.Restraints

3.5.2.1.Availability of alternative therapies
3.5.2.2.Drug exploitation
3.5.2.3.Patent expiration of prescription drugs

3.5.3.Opportunity

3.5.3.1.Advancements in drug development

3.5.4.Impact Analysis

3.6.COVID-19 impact analysis for U.S. Pain Management Drugs

CHAPTER 4:U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.NSAIDS

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast

4.3.Anesthetics

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast

4.4.Anticonvulsants

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast

4.5.Antimigraine drug

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast

4.6.Antidepressants

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast

4.7.Opioids

4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast

4.8.Non-narcotic analgesics

4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast

CHAPTER 5:U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Arthritic pain

5.2.1.Market size and forecast

5.3.Neuropathic pain

5.3.1.Market size and forecast

5.4.Cancer pain

5.4.1.Market size and forecast

5.5.Chronic back pain

5.5.1.Market size and forecast

5.6.Post-operative pain

5.6.1.Market size and forecast

5.7.Migraine

5.7.1.Market size and forecast

5.8.Fibromyalgia

5.8.1.Market size and forecast

5.9.Bone fracture

5.9.1.Market size and forecast

5.10.Muscle sprain/strain

5.10.1.Market size and forecast

5.11.Acute appendicitis

5.11.1.Market size and forecast

5.12.Others

5.12.1.Market size and forecast

CHAPTER 6:PAIN MANAGEMENT DRUGS, BY PAIN TYPE

6.1.Overview

6.1.1.Market size and forecast

6.2.Chronic pain

6.2.1.Market size and forecast

6.3.Acute pain

6.3.1.Market size and forecast

CHAPTER 7:COMPANY PROFILES

7.1.ABBOTT LABORATORIES

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.BOEHRINGER INGELHEIM INTERNATIONAL GMBH

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance

7.3.ELI LILY AND COMPANY

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments

7.4.GLAXOSMITHKLINE PLC (GSK)

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance.
7.4.6.Key strategic moves and developments

7.5.JOHNSON & JOHNSON

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.MERCK & CO., INC.

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments

7.7.MYLAN N.V.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments

7.8.NOVARTIS INTERNATIONAL AG

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.PFIZER INC.

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments

7.10.PURDUE PHARMA L.P.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Key strategic moves and developments

LIST OF TABLES

TABLE 01.PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 03.PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 04.ABBOTT: COMPANY SNAPSHOT
TABLE 05.ABBOTT: OERATING SEGMENT
TABLE 06.ABBOTT: PRODUCT PORTFOLIO
TABLE 07.BOEHRINGER INGELHEIM : COMPANY SNAPSHOT
TABLE 08.BOEHRINGER INGELHEIM : OPERATING SEGMENTS
TABLE 09.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 10.ELI LILLY: COMPANY SNAPSHOT
TABLE 11.LILLY: OPERATING SEGMENTS
TABLE 12.ELI LILLY: PRODUCT PORTFOLIO
TABLE 13.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 14.GSK: COMPANY SNAPSHOT
TABLE 15.GSK: OPERATING SEGMENTS
TABLE 16.GSK: PRODUCT PORTFOLIO
TABLE 17.J&J: COMPANY SNAPSHOT
TABLE 18.J&J: OPERATING BUSINESS SEGMENTS
TABLE 19.J&J: PRODUCT PORTFOLIO
TABLE 20.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 21.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 22.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 23.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 24.MYLAN: COMPANY SNAPSHOT
TABLE 25.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 26.MYLAN: PRODUCT PORTFOLIO
TABLE 27.NOVARTIS: COMPANY SNAPSHOT
TABLE 28.NOVARTIS: OPERATING SEGMENTS
TABLE 29.NOVARTIS: PRODUCT PORTFOLIO
TABLE 30.PFIZER: COMPANY SNAPSHOT
TABLE 31.PFIZER: OERATING SEGMENT
TABLE 32.PFIZER: PRODUCT PORTFOLIO
TABLE 33.PURDUE: COMPANY SNAPSHOT
TABLE 34.PURDUE: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 05.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 06.TOP PLAYER POSTIONING, 2019
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 09.MODERATE THREAT OF SUBSTITUTES
FIGURE 10.MODEARTE THREAT OF NEW ENTRANTS
FIGURE 11.MODERATE COMPETITIVE OF RIVALRY
FIGURE 12.IMPACT ANALYSIS, U.S. PAIN MANAGEMENT DRUGS MARKET
FIGURE 13.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS, 2019-2027 ($MILLION)
FIGURE 14.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANAESTHETIC, 2019-2027 ($MILLION)
FIGURE 15.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANTS, 2019-2027 ($MILLION)
FIGURE 16.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANTI-MIGRAINE AGENTS, 2019-2027 ($MILLION)
FIGURE 17.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANTS, 2019-2027 ($MILLION)
FIGURE 18.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS, 2019-2027 ($MILLION)
FIGURE 19.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC ANALGESICS, 2019-2027 ($MILLION)
FIGURE 20.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ARTHRITIC PAIN BY, 2019-2027 ($MILLION)
FIGURE 21.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN, 2019-2027 ($MILLION)
FIGURE 22.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CANCER PAIN, 2019-2027 ($MILLION)
FIGURE 23.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC BACK PAIN, 2019-2027 ($MILLION)
FIGURE 24.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN, 2019-2027 ($MILLION)
FIGURE 25.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINE, 2019-2027 ($MILLION)
FIGURE 26.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA, 2019-2027 ($MILLION)
FIGURE 27.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR BONE FRACTURE, 2019-2027 ($MILLION)
FIGURE 28.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR MUSCLE STRAIN/SPRAIN, 2019-2027 ($MILLION)
FIGURE 29.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE APPENDICITIS, 2019-2027 ($MILLION)
FIGURE 30.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR OTHERS, 2019-2027 ($MILLION)
FIGURE 31.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN, 2019-2027 ($MILLION)
FIGURE 32.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE PAIN, 2019-2027 ($MILLION)
FIGURE 33.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.BOEHRINGER INGELHEIM: NET SALES, 2017–2019 ($MILLION)
FIGURE 37.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 38.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 39.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 40.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 41.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 42.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 43.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 44.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 45.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 46.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 47.MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 49.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 50.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 51.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 52.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 53.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 54.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 55.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 56.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 57.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)

 
 

The demand for pain management drugs has increased rapidly over the recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors toward the market growth. Presence of large geriatric population base, rise in prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases contribute to the growth of the market. 

However, patent expiration of major best-seller drugs such as pregabalin and duloxetine by Pfizer and Eli Lilly & Co., respectively, and availability of alternative therapies such as acupuncture, massage, and medical devices hamper the market growth.

Employment of pain management drugs is the highest in the U.S., owing to increase in adoption of these drugs, high prevalence of chronic diseases, and increase in disposable income of customers in the U.S. In addition, presence of a large geriatric population and favorable regulatory & healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010 supplement the market growth. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth. 
 

 
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. A wide range of drugs are used to manage pain resulting from inflammation in response to tissue damage, chemical agents/pathogens (nociceptive pain) or nerve damage (neuropathic pain).

A. Pain is a general term that describes uncomfortable sensations in the body. It stems from activation of the nervous system. Pain can range from annoying to debilitating, and it can feel like a sharp stabbing or a dull ache. Pain can also be described as throbbing, stinging, sore, and pinching.

A. The major factor that fuels the growth of the global U.S. Pain Management Drugs Market includes rise in incidences of chronic diseases, favorable regulatory scenario, and increase in geriatric population drive the growth of the U.S. pain management drugs market.However, Availability of alternative therapies and drug exploitation are expected to hamper the market growth.

A. The total market value of U.S. Pain Management Drugs Market is $31,499.07 million in 2019.

A. The forcast period for U.S. Pain Management Drugs Market is 2020 to 2027

A. The market value of U.S. Pain Management Drugs Market in 2027 is $39,356.45 million.

A. The base year is 2019 in U.S. Pain Management Drugs Market

A. Top companies such as Pfizer, Purdue Pharma, Eli Lilly and others held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. In drug class segment Opioids is the most influencing segment. This is attributed to surge in prevalence of hematological diseases and rise in accidents.By application, the global U.S. Pain Management Drugs Market is bifurcated into therapeutic and research.

A. Increase in R&D activities for development of novel drugs with fewer side-effects and regulatory authorities designate certain rapid-track production drugs to speed up regulatory approvals and market entry processes. This is due to improvement in health awareness, development in healthcare infrastructure, and rise in number of hospitals equipped with advanced medical facilities.

Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
U.S. Pain Management Drugs Market

  • Data Pack
  • $2,038
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $3,249
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $3,423
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $4,774
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers